ONXEO

ONXEO

Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and Validive, which completed Phase II clinical trial for the treatment of oral... mucositis in patients treated for a head and neck cancer. Onxeo SA has a collaboration and licensing agreement with Spectrum Pharmaceuticals for the development of Beleodaq; a license agreement with Monopar Therapeutics Inc. to develop Validive; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as BioAlliance Pharma SA and changed its name to Onxeo SA in July 2014. Onxeo SA was founded in 1997 and is headquartered in Paris, France.

Onxeo_logo

Industry:
Company

Founded:
2014

Address:
49, Boulevard Du GEnEral Martial Valin, Paris, France Zipcode 75015

Country:
United Kingdom

Phone:
33 1 45 58 76 00

Market Cap:
72.27M
Total Revenue:
4.29M
Total Assets:
37.63M
Total Cash:
5.71M

Subsidiaries: TopoTarget UK Limited · DNA Therapeutics · TopoTarget Switzerland

Website Url:
http://www.onxeo.com


Key Executives
Name Title Pay Year Born
Ms. Judith Greciet CEO & Director 455,498$ 1968(52 years old)
Mr. Nicolas Fellmann CFO & Admin. and Fin. Director N/A 1968(52 years old)
Dr. Françoise Bono Ph.D. Chief Scientific Officer N/A N/A
Ms. Audrey Legentil-Dumery Director of HR N/A N/A
Mr. Michel Forest Chief Pharmacist & Quality Assurance Director N/A N/A
Mr. Philippe M. Maitre Chief of US Operations & Exec. VP N/A 1957(63 years old)
Dr. Olivier de Beaumont M.D., MBA Chief Medical Officer N/A N/A



Financial & Stock
Company's stock symbol is 0NWK.L. Lastest price : 1.2790. Total volume :5.65k Click reload if you want to check the lastest price on market!!!


Site Inspections: http://www.onxeo.com

  • Host name: 212.227.205.197
  • IP address: 212.227.205.197
  • Location: Woerth am Rhein Germany
  • Latitude: 49.0489
  • Longitude: 8.2596
  • Timezone: Europe/Berlin
  • Postal: 76744

Loading ...
Loading ...


More informations about "Onxeo" on Search Engine

Onxeo – Onxeo designs and develops novel oncology drugs

Onxeo.com Onxeo is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Our approach is based upon a unique mechanism of action of decoy agonist interfering with DNA Damage Response.

Onxeo – Onxeo designs and develops novel oncology drugs

Onxeo.com Onxeo is a clinical-stage biotechnology company designing and developing novel …

Onxeo – Onxeo designs and develops novel oncology drugs

Onxeo.com Onxeo. Onxeo designs and develops novel oncology drugs targeting tumor DNA repair …

Onxeo – Onxeo designs and develops novel oncology drugs

Onxeo.com Appointed Chief Executive Officer of Onxeo in 2011 (BioAlliance Pharma until 2014), …

Onxeo – Onxeo designs and develops novel oncology drugs

Onxeo.com Onxeo is a clinical-stage biotechnology company designing and developing novel …

Onxeo – Onxeo designs and develops novel oncology drugs

Onxeo.com Onxeo is a French clinical-stage biotechnology company designing and developing novel …

Onxeo – Onxeo designs and develops novel oncology drugs

Onxeo.com platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy …

Onxeo – Onxeo designs and develops novel oncology drugs

Onxeo.com At its meeting on September 17, 2020, the Board of Directors of Onxeo co-opted Mr. …

Onxeo – Onxeo designs and develops novel oncology drugs

Onxeo.com Onxeo will publish its annual results on April 21, 2021. The Annual General Meeting will …

Onxeo – Onxeo designs and develops novel oncology drugs

Onxeo.com Onxeo. Onxeo designs and develops novel oncology drugs targeting tumor DNA repair …

ONXEO (OXNXF) Stock Price, News, Quote & History - Yahoo

Finance.yahoo.com Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of …

Onxeo SA (ONXEO.CO) Stock Price, News, Quote & History

Finance.yahoo.com Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of …

ONXEO Stock Quote - Onxeo SA - Bloomberg Markets

Bloomberg.com About Onxeo SA Onxeo SA is a biopharmaceutical company specialized in the development of therapeutics targeting drug resistance in cancer, HIV and other severe and opportunistic infections. The...

Onxeo | Share Price, Company News & Analysis | Edison

Edisongroup.com Onxeo has a proprietary platON platform based on a unique decoy technology in the field of DNA damage repair inhibition. The compounds have been shown in preclinical studies to be synergistic with DNA breaking therapies and also have an ability to reverse tumour resistance to …

Onxeo S.A. | LinkedIn

Linkedin.com Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a French biotechnology company developing innovative oncology drugs based on DNA-targeting and epigenetics, two of the most sought-after...

Onxeo Announces Enrollment of First Patient in Phase Ib/II

Globenewswire.com Oct 21, 2020 · Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting …

ONXEO Cours Action ALONX, Cotation Bourse Euronext Paris

Boursorama.com Le cours de l'action ONXEO ALONX en temps réel sur Boursorama : historique de la cotation sur Euronext Paris, graphique, actualités, consensus des analystes et informations boursières

Onxeo S.A.: Onxeo Publishes Letter to Shareholders and

Finanznachrichten.de Feb 03, 2021 · Onxeo (Euronext Growth: ALONX, Nasdaq First North: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique ...

ONXEO:FN Denmark Stock Quote - Onxeo SA - Bloomberg Markets

Bloomberg.com About Onxeo SA Onxeo SA is a biopharmaceutical company specialized in the development of therapeutics targeting drug resistance in cancer, HIV and other severe and opportunistic infections. The...

Onxeo S.A.: Onxeo Announces the Success of Its Rights

Finanznachrichten.de Apr 13, 2021 · Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of ...

Onxeo to Present New Preclinical Data at AACR 2021 Paris

Globenewswire.com Apr 08, 2021 · Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of ...

ONXEO | Onxeo S.A. Stock Price & News - WSJ

Wsj.com View the latest Onxeo S.A. (ONXEO) stock price, news, historical charts, analyst ratings and financial information from WSJ.

ONXEO, Onxeo, (FR0010095596) - Nasdaq

Nasdaqomxnordic.com 2 Mkt Cap indicates the market value of the selected share series admitted to trading on Nasdaq Nordic. Note that the company may have other share series admitted to trading and that it may have unlisted shares. For complete information, please visit the company’s website.

Onxeo Receives Notice of Intent to Grant a New Patent

Businesswire.com Oct 22, 2020 · Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of ...

Onxeo Company Profile: Stock Performance & Earnings

Pitchbook.com Onxeo SA is a biotechnology company that is engaged in developing oncology drugs based on tumor DNA targeting.

Onxeo - Crunchbase Company Profile & Funding

Crunchbase.com Feb 29, 2016 · Onxeo is a biotechnology company that develops drugs for oncology.

Onxeo to Present New Preclinical Data at AACR 2021

Tmcnet.com Apr 08, 2021 · Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR).

Onxeo Announces the Success of Its Rights Issue With €9.7

Markets.businessinsider.com Apr 13, 2021 · Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting …

Belinostat - Onxeo - AdisInsight

Adisinsight.springer.com Belinostat - Onxeo Alternative Names: Beleodaq; CLN-9; PDX 101; PX-105684; PXD 101 Latest Information Update: 14 Apr 2020. Price : $50 * Buy Profile. Adis is an information provider. We do not sell or distribute actual drugs. Final gross price and currency may …

Onxeo Announces Approval of the REVocan Study by

Biospace.com May 29, 2020 · Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds ...

Onxeo buys DNA Therapeutics, seeks funding partner for

Fiercebiotech.com Feb 29, 2016 · Onxeo has acquired DNA Therapeutics for €1.7 million ($1.85 million) and set out on a search for a new partner to help fund late-stage studies for its delayed drug Validive.

Onxeo - Next generation of DNA damage repair inhibitors

Edisongroup.com Sep 16, 2019 · Onxeo could also explore the potential to combine belinostat with future compounds from the platON platform. Onxeo has published proof-of-concept in vitro data supporting the rationale. The findings demonstrated that there was a clear synergistic effect on malignant cells compared with monotherapy of either of the drugs (AsiDNA or belinostat).

ONXEO S.A. : Shareholders Board Members Managers and

Marketscreener.com Onxeo is a biotechnology company specializing in the development of innovative oncology medicines based on DNA-targeting and epigenetics, two of the most anticipated mechanisms of action in the treatment of cancer today.

Onxeo Announces Enrollment of First Patient in Phase Ib/II

Biospace.com Oct 21, 2020 · Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds ...

Onxeo : Will Publish Its Annual Results on April 21, 2021

Marketscreener.com Onxeo (Euronext Growth: ALONX, Nasdaq First North: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive ...

ONXEO SA 0NWK Market Stock | London Stock Exchange

Londonstockexchange.com ONXEO SA 0NWK Overview - Search stock, chart, recent trades, company information, trading information, company news, fundamentals

ONXEO Stock Price and Chart — OMXCOP:ONXEO — TradingView

Tradingview.com Onxeo SA is a is a clinical-stage biotechnology company. It engages in the development of drugs for the treatment of orphan diseases. The firm produces and develops ophan oncology products under the brand names Livatag, Validive, Beleodaq and AsiDNA.

onxeo (@onxeo_) | Twitter

Twitter.com The latest tweets from @Onxeo_

Onxeo Will Publish Its Annual Results on April 21, 2021

Streetinsider.com Onxeo (Euronext Growth: ALONX, Nasdaq First North: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique ...

Onxeo finds a partner to progress its cancer medication

Biopharmadive.com Sep 13, 2017 · Onxeo S.A. has been searching for a partner to help develop its drug for a side effect of cancer treatment. On Wednesday, the company announced Monopar Therapeutics LLC is filling that void. Through an exclusive licensing deal, Onxeo is taking home $1 million upfront and stands to receive up to $108 million more in milestone payments.

Etidaligide - Onxeo - AdisInsight

Adisinsight.springer.com 29 Jan 2020 Onxeo in collaboration with Gustave Roussy plans a phase Ib/II REVOCAN trial for Ovarian cancer (Combination therapy, Second line therapy and greater) in the first semester of 2020 04 Nov 2019 Onxeo receives a Notice of Allowance for a patent protecting etidaligide in combination with any PARP inhibitor for the treatment of Cancer ...

Onxeo (ENXTPA:ALONX) - Share price, News & Analysis

Simplywall.st Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for …

Should You Buy ONXEO.CO Stock?

Stockinvest.us ONXEO.CO Stock Risk In general the stock tends to have very controlled movements and therefore the general risk is considered very low. However, be aware of low or falling volume and make sure to keep an eye on the stock During the last day, the stock moved 0.0000 kr between high and low, or 0.0000%.For the last week the stock has had a daily average volatility of 2.77%

Onxeo: An Upcoming Mid-Sized Pharma With Ambitions

Seekingalpha.com Mar 12, 2015 · Onxeo ()-- listed on both Euronext Paris and Nasdaq OMX Copenhagen under ticker 'ONXEO' -- is a French/Danish biotech building a portfolio of …

Onxeo SA (ONXEO) Stock Price History | wallmine

Wallmine.com Onxeo SA, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of relapsed or refractory peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage ...

Onxeo Stock Quote. ONXEO - Stock Price, News, Charts

Advfn.com Onxeo (ONXEO) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. 01/04/2021 14:11:30 1-888-992-3836 Free Membership Login

| live

Live.euronext.com Onxeo présentera de nouvelles données précliniques à l’AACR 2021 08/04/2021 Onxeo to Present New Preclinical Data at AACR 2021 24/03/2021 Onxeo Will Publish Its Annual Results on April 21, 2021 24/03/2021 Onxeo publiera ses résultats annuels le 21 avril 2021 10/03/2021

PD-1 Inhibitor Market 2021-28 Booming Trends with Merck

Ksusentinel.com Mar 04, 2021 · PD-1 Inhibitor Market 2021-28 Booming Trends with Merck, Novartis, Onxeo, Sumitomo Dainippon Pharma, Taiwan Liposome Company, Tiziana Life Sciences, Genentech (Roche), AstraZeneca, Pfizer. rc March 4, 2021. 52 . PD-1 Inhibitor Market PD-1 is a checkpoint protein on immune cells called T cells. It normally acts as a type of off switch that helps ...

| live

Live.euronext.com Onxeo Will Publish Its Annual Results on April 21, 2021 24/03/2021 Onxeo publiera ses résultats annuels le 21 avril 2021 10/03/2021 Onxeo Launches a Rights Issue to Accelerate Its R&D Programs 10/03/2021 Onxeo lance une augmentation de capital avec maintien du …

Onxeo : un analyste met le feu au titre - Boursier.com

Boursier.com Actualités Onxeo (ex-BioAlliance Pharma) 26/03. Démarrer plus d'études cliniques et obtenir plus de données pour AsiDNA. 25/03. Onxeo publiera ses résultats annuels le 21 avril ...

Onxeo to Acquire DNA Therapeutics - genengnews

Genengnews.com Onxeo agreed to acquire DNA Therapeutics for the upfront payment as well as €1 million (about $1.1 million) in cash or Onxeo shares upon successful initiation of a Phase II trial in a selected ...

Onxeo receives $25M milestone payment from Spectrum on

Thepharmaletter.com News Onxeo to present data supporting three key orphan oncology assets at AACR Annual Meeting. 23-03-2017. News Merck Canada is proud to partner with Innovative Medicines Canada and other pharmaceutical member companies to help protect healthcare workers with a . 04-04-2020. News Gene therapy for rare eye disease set to be offered on NHS. 04-09 ...

ONXEO Stock Price | Onxeo S.A. Stock Quote (Denmark: OMX)

Marketwatch.com ONXEO | Complete Onxeo S.A. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Working at ONEOK: 148 Reviews | Indeed.com

Indeed.com 148 reviews from ONEOK employees about ONEOK culture, salaries, benefits, work-life balance, management, job security, and more.